Advancing a targeted, non-opioid biologic therapy through late-stage clinical evaluation across high-impact musculoskeletal indications, with a scalable platform for long-term expansion.
Lead Candidate: Targeted Non-Opioid Biologic Therapy
Status: Preclinical → IND-Enabling (2026) → Phase III Clinical Trials (mid-2026)
Clinical Trials Launching
2026
Our Phase III studies across multiple US sites will evaluate safety, dosing, and early efficacy in acute MSK pain across four orthopaedic indications.
Indications
Targeted development across high-impact musculoskeletal and procedural pain settings.
Acute Musculoskeletal Injury
Covers common soft-tissue and joint injuries where localized pain and inflammation drive acute functional limitation. Designed for rapid, tissue-specific pain modulation without systemic exposure.
Example conditions
-
Sprains and strains
-
Ligament and tendon injuries
-
Acute joint trauma
Post-Operative Pain
Addresses acute pain following orthopaedic procedures where early mobilization and opioid-sparing strategies are critical to recovery.
Example procedures
-
Arthroscopy
-
Joint repair and reconstruction
-
Soft-tissue surgical interventions
Sports Medicine & Soft-Tissue Injury
Targets high-demand patients requiring fast recovery and durable pain relief with minimal side-effect risk.
Use cases
-
Athletic injuries
-
Overuse injuries
-
Training-related musculoskeletal stress
Robust Long-Term Pipeline
ARCK’s robust pipeline includes:
